首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

Keytruda 市場規模、佔有率、成長分析（按付款者、分銷管道、應用、地區）- 產業預測（2025 年至 2032 年）

市場調查報告書

商品編碼

1772715

Keytruda 市場規模、佔有率、成長分析（按付款者、分銷管道、應用、地區）- 產業預測（2025 年至 2032 年）

Keytruda Market Size, Share, and Growth Analysis, By Payer (Commercial/Private, Public), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy), By Application, By Region - Industry Forecast 2025-2032

出版日期: 2025年07月10日 | 出版商:

SkyQuest | 英文 193 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球 Keytruda 市場規模價值為 282 億美元，預計將從 2024 年的 306.5 億美元成長到 2032 年的 597.5 億美元，預測期內（2025-2032 年）的複合年成長率為 8.7%。

全球 Keytruda 市場受到多種癌症核准適應症大幅擴張的推動，包括肺癌、黑色素瘤、胃癌、子宮頸癌和子宮內膜癌。在疾病早期階段和聯合治療中一致的臨床療效導致醫療保健提供者擴大採用該藥物。儘管專利到期即將到期，但默克公司計劃推出的皮下製劑將提高患者的便利性和簡化給藥，預計仍將提升市場佔有率。然而，市場面臨挑戰，尤其是預期的獨佔權喪失和生物相似藥競爭對手的出現，這可能會影響其在已開發市場和新興市場的發展軌跡。此外，治療成本上升和付款人的抵制也可能阻礙銷售量成長，迫使公司從積極的市場佔有率爭奪轉向對不斷發展的格局的策略管理。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益同比對比（2022-2024 年）

主要企業簡介

Merck & Co. Inc.
Bristol-Myers Squibb Company
AstraZeneca PLC
Roche Holding AG
Pfizer Inc.
Novartis AG
GlaxoSmithKline
Eisai Co., Ltd.
Innovent Biologics
BeiGene
Biomab
Aspen Pharmacare
Johnson & Johnson
Eli Lilly and Company
AbbVie Inc.

結論和建議

簡介目錄

Product Code: SQMIG35I2403

Global Keytruda Market size was valued at USD 28.2 billion in 2023 and is poised to grow from USD 30.65 billion in 2024 to USD 59.75 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).

The global Keytruda market is experiencing significant growth driven by its expanding range of approved indications in various cancers, including lung, melanoma, gastric, cervical, and endometrial. The consistent clinical efficacy observed in early-stage diseases and in combination therapies enhances its adoption among healthcare providers. Merck's anticipated introduction of a subcutaneous formulation is set to improve patient convenience and streamline dosing, thus boosting its market share, even as patent expiration looms. Nonetheless, the market faces challenges, notably the anticipated loss of exclusivity and the emergence of biosimilar competitors, which may impact its trajectory in both developed and emerging markets. Additionally, high treatment costs and payer resistance could inhibit volume growth, prompting a shift in focus from aggressive share acquisition to strategic management of the evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Keytruda market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Keytruda Market Segments Analysis

Global Keytruda Market is segmented by Payer, Distribution Channel, Application and region. Based on Payer, the market is segmented into Commercial/Private and Public. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Specialty Pharmacy. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma, Head & Neck Cancer, Gastric Cancer, Urothelial Cancer and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Keytruda Market

Keytruda's impressive expansion across various cancer types, such as non-small cell lung cancer, melanoma, head and neck cancer, endometrial cancer, and triple-negative breast cancer, has solidified its position in the global market. Each new regulatory approval enhances patient access and boosts physician confidence, positioning Keytruda as a foundational therapy in oncology treatment protocols. The growing significance of PD-1 inhibitors, including Keytruda, within precision oncology is facilitating its application in early-stage and adjuvant treatment settings, thereby ensuring sustained revenue growth and widespread adoption in both developed and emerging markets. This multifaceted approach underscores Keytruda's pivotal role in contemporary cancer care.

Restraints in the Global Keytruda Market

A significant obstacle to the future success of Keytruda lies in the impending expiration of its primary patents in major markets, which could adversely affect its long-term viability. Despite Merck's efforts to extend Keytruda's market presence, the loss of exclusivity is likely to exert pressure on pricing, reimbursement strategies, and overall market share. This challenge is particularly pronounced in high-volume therapeutic areas, such as non-small cell lung cancer, where competitive dynamics intensify, and insurers increasingly seek cost containment measures. Such factors may hinder Keytruda's ability to maintain its established position in the global market.

Market Trends of the Global Keytruda Market

The Global Keytruda market is witnessing a significant trend towards early-stage treatment and the expansion of adjuvant therapy, driven by Merck's strategic shift in focus. This transition is fueled by recent approvals from regulatory agencies in the U.S., Europe, and Asia for Keytruda's use in earlier stages of melanoma, non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). Strong clinical data further supports this movement, highlighting improvements in disease-free survival (DFS) and long-term cost-effectiveness. Consequently, this trend not only prolongs therapy duration for patients but also solidifies Merck's competitive advantage by embedding Keytruda deeper into established oncology guidelines.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis

Global Keytruda Market Size by Payer & CAGR (2025-2032)

Market Overview
Commercial/Private
Public

Global Keytruda Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Specialty Pharmacy

Global Keytruda Market Size by Application & CAGR (2025-2032)

Market Overview
Lung Cancer
Breast Cancer
Melanoma
Hodgkin Lymphoma
Head & Neck Cancer
Gastric Cancer
Urothelial Cancer
Others

Global Keytruda Market Size & CAGR (2025-2032)

North America (Payer, Distribution Channel, Application)
- US
- Canada
Europe (Payer, Distribution Channel, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Payer, Distribution Channel, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Payer, Distribution Channel, Application)
- Brazil
- Rest of Latin America
Middle East & Africa (Payer, Distribution Channel, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Innovent Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeiGene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomab
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Pharmacare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments